People with COPD are vulnerable to small increases in PM2.5, with each 1 μg/m3 rise in long-term exposure linked to a 3.8% ...

Researchers warn of increased cannabis use among older US adults, as experts link it to health risks and complications in ...

Paris: Sanofi has announced that the AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company announced mixed results ...

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically me ...

A new device was able to distinguish between mild and very severe chronic obstructive pulmonary disease (COPD).

The AERIFY program includes two additional ongoing trials: AERIFY-3, a Phase 2 mechanistic study assessing the impact of itepekimab on airway inflammation in patients with COPD, and AERIFY-4, a Phase ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

India’s active COVID-19 caseload has surpassed the 4,000 mark, with Kerala reporting the highest number of cases, followed by ...

Nucala's approval offers hope for uncontrolled COPD. This new drug reduces flare-ups, a key benefit for Black Americans.